RDX-002 program

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameRDX-002 program
Drug Alias NameNaP2b inhibitors (Sanofi)hyperphosphatemia therapy (Ardelyx)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium-dependent phosphate transport protein 2B inhibitors
TargetsSodium-dependent phosphate transport protein 2B
Therapy Area/IndicationsHyperphosphatemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesArdelyx Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiArdelyx Inc
Active IndicationsN/A
Inactive IndicationsHyperphosphatemia

Other Information

ATC CodeN/A
Related LinksN/A